{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:22:52Z","timestamp":1792664572573,"version":"4.5.0"},"reference-count":96,"publisher":"American Medical Association (AMA)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2020,11,17]]},"DOI":"10.1001\/jama.2020.17598","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T11:00:49Z","timestamp":1605610849000},"page":"1980","source":"Crossref","is-referenced-by-count":1554,"title":["Bladder Cancer"],"prefix":"10.1001","volume":"324","author":[{"given":"Andrew T.","family":"Lenis","sequence":"first","affiliation":[{"name":"Institute of Urologic Oncology (IUO), Department of Urology, David Geffen School of Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Lec","sequence":"additional","affiliation":[{"name":"Institute of Urologic Oncology (IUO), Department of Urology, David Geffen School of Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Chamie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MD,","family":"MSHS","sequence":"additional","affiliation":[{"name":"Institute of Urologic Oncology (IUO), Department of Urology, David Geffen School of Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"jrv200011r1","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: an update.","volume":"38","author":"Richters","year":"2020","journal-title":"World J Urol."},{"issue":"1","key":"jrv200011r2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v69.1","article-title":"Cancer statistics, 2019.","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"jrv200011r3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline.","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"3","key":"jrv200011r4","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline.","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"key":"jrv200011r8"},{"issue":"6","key":"jrv200011r10","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","article-title":"Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018.","volume":"74","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"issue":"3","key":"jrv200011r11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/bju.2010.105.issue-3","article-title":"The effect of age and gender on bladder cancer: a critical review of the literature.","volume":"105","author":"Shariat","year":"2010","journal-title":"BJU Int"},{"issue":"6","key":"jrv200011r12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.urolonc.2009.07.020","article-title":"Bladder cancer in the elderly.","volume":"27","author":"Shariat","year":"2009","journal-title":"Urol Oncol"},{"issue":"1","key":"jrv200011r13","doi-asserted-by":"publisher","first-page":"12521","DOI":"10.1038\/s41598-018-29987-2","article-title":"Racial differences in urinary bladder cancer in the United States.","volume":"8","author":"Wang","year":"2018","journal-title":"Sci Rep"},{"issue":"10","key":"jrv200011r14","doi-asserted-by":"publisher","first-page":"469.e1","DOI":"10.1016\/j.urolonc.2018.07.012","article-title":"Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy.","volume":"36","author":"Gild","year":"2018","journal-title":"Urol Oncol"},{"issue":"2","key":"jrv200011r15","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.eururo.2015.08.037","article-title":"Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes.","volume":"69","author":"Dobruch","year":"2016","journal-title":"Eur Urol"},{"issue":"5","key":"jrv200011r16","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ccell.2017.08.005","article-title":"Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency.","volume":"32","author":"Hurst","year":"2017","journal-title":"Cancer Cell"},{"issue":"7","key":"jrv200011r17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association between smoking and risk of bladder cancer among men and women.","volume":"306","author":"Freedman","year":"2011","journal-title":"JAMA"},{"issue":"6917","key":"jrv200011r18","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer.","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"Aug","key":"jrv200011r19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3389\/fmed.2018.00223","article-title":"Understanding urogenital schistosomiasis-related bladder cancer: an update.","volume":"5","author":"Ishida","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"jrv200011r20","doi-asserted-by":"publisher","first-page":"i851","DOI":"10.1136\/bmj.i851","article-title":"Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis.","volume":"352","author":"Wallis","year":"2016","journal-title":"BMJ"},{"issue":"2","key":"jrv200011r21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.eururo.2018.09.034","article-title":"External beam radiotherapy increases the risk of bladder cancer when compared with radical prostatectomy in patients affected by prostate cancer.","volume":"75","author":"Moschini","year":"2019","journal-title":"Eur Urol"},{"issue":"8","key":"jrv200011r22","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.urolonc.2012.04.006","article-title":"The characteristics of bladder cancer after radiotherapy for prostate cancer.","volume":"31","author":"Abern","year":"2013","journal-title":"Urol Oncol"},{"issue":"10","key":"jrv200011r23","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1136\/ard.2003.019125","article-title":"Urinary bladder cancer in Wegener\u2019s granulomatosis: risks and relation to cyclophosphamide.","volume":"63","author":"Knight","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"jrv200011r24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.radonc.2017.02.007","article-title":"Secondary malignancies after rectal cancer resection with and without radiation therapy: a propensity-adjusted, population-based SEER analysis.","volume":"123","author":"Warschkow","year":"2017","journal-title":"Radiother Oncol"},{"issue":"21","key":"jrv200011r25","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/jnci\/djm201","article-title":"Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk.","volume":"99","author":"Chaturvedi","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"jrv200011r26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial risk and heritability of cancer among twins in Nordic countries.","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"jrv200011r27","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1200\/JCO.19.01395","article-title":"Cancer susceptibility mutations in patients with urothelial malignancies.","volume":"38","author":"Carlo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"jrv200011r28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/MOU.0000000000000639","article-title":"Lynch syndrome and urologic malignancies: a contemporary review.","volume":"29","author":"Lim","year":"2019","journal-title":"Curr Opin Urol"},{"issue":"3","key":"jrv200011r29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3233\/BLC-180180","article-title":"Systematic review: an update on the spectrum of urological malignancies in Lynch syndrome.","volume":"4","author":"Huang","year":"2018","journal-title":"Bladder Cancer"},{"issue":"4","key":"jrv200011r30","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What is the significance of variant histology in urothelial carcinoma?","volume":"6","author":"Lobo","year":"2020","journal-title":"Eur Urol Focus."},{"issue":"7463","key":"jrv200011r31","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"0","key":"jrv200011r32","first-page":"1","article-title":"Advances in risk stratification of bladder cancer to guide personalized medicine.","volume":"7","author":"Matulay","year":"2018","journal-title":"F1000Res"},{"issue":"2","key":"jrv200011r33","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/bju.2006.97.issue-2","article-title":"A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic.","volume":"97","author":"Edwards","year":"2006","journal-title":"BJU Int"},{"issue":"2","key":"jrv200011r34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170819","article-title":"A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer.","volume":"12","author":"Xiong","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"jrv200011r35","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.","volume":"64","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"jrv200011r36","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","article-title":"Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review.","volume":"73","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"issue":"3","key":"jrv200011r37","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/cncr.29071","article-title":"Quality of diagnostic staging in patients with bladder cancer: a process-outcomes link.","volume":"121","author":"Chamie","year":"2015","journal-title":"Cancer"},{"issue":"8","key":"jrv200011r38","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1007\/s00330-020-06802-z","article-title":"Use of Vesical Imaging-Reporting and Data System (VI-RADS) for detecting the muscle invasion of bladder cancer: a diagnostic meta-analysis.","volume":"30","author":"Luo","year":"2020","journal-title":"Eur Radiol"},{"issue":"10","key":"jrv200011r39","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00345-018-2567-1","article-title":"Diagnostic biomarkers in non-muscle invasive bladder cancer.","volume":"37","author":"Faiena","year":"2019","journal-title":"World J Urol"},{"issue":"35","key":"jrv200011r40","doi-asserted-by":"publisher","first-page":"59527","DOI":"10.18632\/oncotarget.v8i35","article-title":"The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies.","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"18","key":"jrv200011r41","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma.","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"jrv200011r42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis.","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"issue":"3","key":"jrv200011r43","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/JU.0000000000000593","article-title":"Use and validation of the AUA\/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort.","volume":"203","author":"Ritch","year":"2020","journal-title":"J Urol"},{"issue":"3","key":"jrv200011r44","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review.","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur Urol"},{"issue":"6 pt 1","key":"jrv200011r45","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","article-title":"A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials.","volume":"171","author":"Sylvester","year":"2004","journal-title":"J Urol"},{"issue":"4","key":"jrv200011r46","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1046\/j.1464-410x.1999.00951.x","article-title":"Perivesical fat necrosis after adjuvant intravesical chemotherapy.","volume":"83","author":"Doherty","year":"1999","journal-title":"BJU Int"},{"issue":"18","key":"jrv200011r47","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial.","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"issue":"10","key":"jrv200011r48","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer.","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"1","key":"jrv200011r49","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"issue":"1","key":"jrv200011r50","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","article-title":"Side effects of bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG.","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"issue":"4","key":"jrv200011r51","first-page":"145","article-title":"Intravesical therapy for non-muscle invasive bladder cancer\u2014current and future options in the age of bacillus Calmette-Guerin shortage.","volume":"21","author":"Golla","year":"2019","journal-title":"Rev Urol"},{"issue":"4","key":"jrv200011r52","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.euf.2018.06.018","article-title":"Manufacturing and the market: rationalizing the shortage of bacillus Calmette-Gu\u00e9rin.","volume":"4","author":"Bandari","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"3","key":"jrv200011r53","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder.","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"issue":"5","key":"jrv200011r54","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer.","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol."},{"key":"jrv200011r55","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.2019.37.7_suppl.350","article-title":"Keynote 057: phase II trial of pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin (BCG).","volume":"37","author":"Balar","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"jrv200011r56","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3233\/BLC-160053","article-title":"Summary and recommendations from the National Cancer Institute\u2019s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.","volume":"2","author":"Lerner","year":"2016","journal-title":"Bladder Cancer"},{"issue":"5","key":"jrv200011r57","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1097\/JU.0000000000000350","article-title":"A nationwide, population based analysis of patients with organ confined, muscle invasive bladder cancer not receiving curative intent therapy in Sweden from 1997 to 2014.","volume":"202","author":"Westergren","year":"2019","journal-title":"J Urol"},{"issue":"9","key":"jrv200011r58","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv200011r59","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis.","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"issue":"9","key":"jrv200011r60","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1002\/cncr.v113:9","article-title":"A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.","volume":"113","author":"Dash","year":"2008","journal-title":"Cancer."},{"issue":"17","key":"jrv200011r61","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"jrv200011r62","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.eururo.2014.09.007","article-title":"Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.","volume":"67","author":"Zargar","year":"2015","journal-title":"Eur Urol"},{"issue":"17","key":"jrv200011r63","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy.","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"jrv200011r64","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline.","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol."},{"issue":"34","key":"jrv200011r65","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study.","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"jrv200011r66","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies.","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"jrv200011r67","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv200011r68","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1016\/S1569-9056(14)60119-6","article-title":"Does the extent of lymphadenectomy impact survival after radical cystectomy: a systematic review.","volume":"13","author":"Bruins","year":"2014","journal-title":"Eur Urol Suppl."},{"issue":"4","key":"jrv200011r69","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.eururo.2018.09.047","article-title":"Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial.","volume":"75","author":"Gschwend","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"jrv200011r70","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.eururo.2007.09.008","article-title":"Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions.","volume":"53","author":"Nieuwenhuijzen","year":"2008","journal-title":"Eur Urol"},{"issue":"3","key":"jrv200011r71","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00345-017-2169-3","article-title":"Trends in urinary diversion after radical cystectomy for urothelial carcinoma.","volume":"36","author":"Bachour","year":"2018","journal-title":"World J Urol"},{"issue":"1","key":"jrv200011r72","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2008.07.031","article-title":"Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology.","volume":"55","author":"Shabsigh","year":"2009","journal-title":"Eur Urol"},{"issue":"3, pt 1","key":"jrv200011r73","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0022-5347(05)00421-0","article-title":"A critical analysis of perioperative mortality from radical cystectomy.","volume":"175","author":"Quek","year":"2006","journal-title":"J Urol"},{"issue":"9","key":"jrv200011r74","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/cncr.28586","article-title":"Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer.","volume":"120","author":"Hu","year":"2014","journal-title":"Cancer"},{"issue":"2","key":"jrv200011r75","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1046\/j.1464-410X.2003.04000.x","article-title":"Metabolic and functional consequences of urinary reconstruction with bowel.","volume":"91","author":"Gerharz","year":"2003","journal-title":"BJU Int"},{"issue":"10","key":"jrv200011r76","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jamasurg.2018.1680","article-title":"Comparing survival outcomes and costs associated with radical cystectomy and trimodal therapy for older adults with muscle-invasive bladder cancer.","volume":"153","author":"Williams","year":"2018","journal-title":"JAMA Surg"},{"issue":"22","key":"jrv200011r77","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1002\/cncr.v123.22","article-title":"Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.","volume":"123","author":"Cahn","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"jrv200011r78","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","article-title":"Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"},{"issue":"4","key":"jrv200011r79","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.juro.2012.06.029","article-title":"Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? a matched case-control analysis.","volume":"188","author":"Knoedler","year":"2012","journal-title":"J Urol"},{"issue":"1","key":"jrv200011r80","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur J Cancer"},{"issue":"17","key":"jrv200011r81","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv200011r82","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","article-title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.","volume":"16","author":"Sternberg","year":"2015","journal-title":"Lancet Oncol"},{"issue":"11","key":"jrv200011r83","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma.","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"jrv200011r84","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10122","key":"jrv200011r85","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"jrv200011r86","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"jrv200011r87","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study.","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"issue":"19","key":"jrv200011r88","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study.","volume":"35","author":"Apolo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"jrv200011r89","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma.","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"29","key":"jrv200011r90","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy.","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"jrv200011r91","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1200\/JCO.2020.38.6_suppl.441","article-title":"Study EV-103: preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"jrv200011r92","doi-asserted-by":"publisher","first-page":"v890","DOI":"10.1093\/annonc\/mdz394.049","article-title":"Initial results from TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of platinum-based regimens (PLT) or immunotherapy.","volume":"30","author":"Tagawa","year":"2019","journal-title":"Ann Oncol"},{"issue":"10","key":"jrv200011r93","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/COC.0000000000000585","article-title":"Systematic literature review and meta-analysis of response to first-line therapies for advanced\/metastatic urothelial cancer patients who are cisplatin ineligible.","volume":"42","author":"Freshwater","year":"2019","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"jrv200011r94","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.juro.2016.02.3005","article-title":"Immunotherapy for the treatment of urothelial carcinoma.","volume":"197","author":"Donin","year":"2017","journal-title":"J Urol"},{"issue":"1","key":"jrv200011r95","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat Commun"},{"issue":"2","key":"jrv200011r96","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11912-020-0879-y","article-title":"Antibody-drug conjugates in urothelial carcinomas.","volume":"22","author":"Sarfaty","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"jrv200011r5","unstructured":"Barocas? DA, Boorjian? SA, Alvarez? R, . Microhematuria: AUA\/SUFU guideline. American Urological Association. Published 2020. Accessed June 28, 2020. https:\/\/www.auanet.org\/guidelines\/microhematuria"},{"key":"jrv200011r6","unstructured":"Babjuk? M, Burger? M, Comperat? E, . European Association of Urology non-muscle invasive bladder cancer guidelines. Published 2020. Accessed June 21, 2020. https:\/\/uroweb.org\/guideline\/non-muscle-invasive-bladder-cancer\/"},{"key":"jrv200011r7","unstructured":"Witjes? JA, Bruins? HM, Cathomas? R, . European Association of Urology muscle-invasive and metastatic bladder cancer guidelines. Published 2020. Accessed June 21, 2020. https:\/\/uroweb.org\/guideline\/bladder-cancer-muscle-invasive-and-metastatic\/"},{"key":"jrv200011r9","unstructured":"Oxford Centre for Evidence-based Medicine: levels of evidence. Updated March 2009. Accessed June 28, 2020. https:\/\/www.cebm.net\/2009\/06\/oxford-centre-evidence-based-medicine-levels-evidence-march-2009\/"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2772966\/jama_lenis_2020_rv_200011_1605024530.47615.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T11:01:04Z","timestamp":1605610864000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2772966"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":96,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2020,11,17]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.17598","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,17]]}}}